Skip to content

Nurix Therapeutics, Inc. NRIX Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$608K

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$2B+40.1%

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s capital investments accrued but not yet paid?
Nurix Therapeutics, Inc. (NRIX) reported capital investments accrued but not yet paid of $1.7M in Q4 2025.
How has Nurix Therapeutics, Inc.'s capital investments accrued but not yet paid changed year-over-year?
Nurix Therapeutics, Inc.'s capital investments accrued but not yet paid increased by 42.2% year-over-year, from $1.2M to $1.7M.